团体行为激活联合常规治疗纤维肌痛合并重性抑郁:随机临床试验设计与方案
本研究为随机临床试验方案,纳入90名纤维肌痛合并重性抑郁的智利女性,评价在常规照护基础上加用团体行为激活(BA)的疗效。主要结局为抑郁症状严重程度,次要结局包括疼痛强度、纤维肌痛影响、疼痛灾难化与过度警觉等。预期BA组在治疗后主要及次要结局改善优于单用常规照护组,并维持至随访。
要点
- 在纤维肌痛合并重性抑郁的智利女性中,评价团体BA联合常规照护的疗效。
- 主要结局为抑郁症状严重程度,采用PHQ-9等量表评估。
- 随访至治疗后3个月,检验疗效是否维持。
核心结论
- 预期团体BA联合常规照护较单用常规照护在主要与次要结局上有更大改善,且具统计学与临床意义并维持至随访。
研究设计与样本
- 随机临床试验方案,纳入90名纤维肌痛合并重性抑郁的智利女性,试验组45名接受常规照护加团体BA,对照组45名仅接受常规照护。
- 评估时点为基线、试验组治疗中(第6至7次会谈之间)、试验组治疗结束时及3个月随访。
- 注册于ClinicalTrials.gov,标识NCT03207828。
主要发现
- 本文为设计方案,未报告疗效结果。
关键数值与推荐
- 主要结局为抑郁症状严重程度,使用智利版PHQ-9评估。
- 次要结局包括疼痛强度(复合疼痛强度指数)、纤维肌痛影响(FIQ-R)、疼痛灾难化(PCS)、疼痛警觉与觉察(PVAQ)、躯体健康症状(PHQ-15)、环境奖励(RPI)及行为激活(BADS激活分量表)。
临床怎么用
- 为纤维肌痛合并重性抑郁患者提供在常规照护基础上加用团体BA的整合治疗证据,待试验结果确认。
局限性
- 本文仅为试验设计与方案,尚无疗效数据;样本为智利女性,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibromyalgia and major depression frequently co-occur. Patients with both conditions have a worse prognosis and higher disability, and their treatment options are scarce. Behavioral activation (BA) may be an especially useful intervention for these patients, as it targets mechanisms of action that seem to be common to both disorders. Nevertheless, its efficacy has not been examined in people with both conditions. We describe the design and rationale of a randomized clinical trial aimed to evaluate the efficacy of adding BA (applied in groups) to usual care in order to reduce the severity of depressive symptoms (primary outcome) among Chilean women with fibromyalgia and major depression (N = 90). Pain intensity, fibromyalgia impact, pain catastrophizing and hypervigilance, physical health symptoms, environmental reward, and BA will be evaluated as secondary outcomes. METHODS: Women will be randomized to an experimental arm (n = 45) which will receive usual care (UC) for fibromyalgia with comorbid depression plus BA; and a comparison arm, which will receive only UC for fibromyalgia with comorbid depression (n = 45). Outcome assessment will take place at four time points: (1) at baseline, (2) when the experimental arm is under treatment (between sessions 6 and 7), (3) immediately after the experimental arm complete the treatment, and (4) at a 3-month follow-up. The following instruments will be used: Chilean version of the Patient Health Questionnaire-9 (PHQ-9), Composed Pain Intensity Index, Fibromyalgia Impact Questionnaire Revised (FIQ-R), Pain Catastrophizing Scale (PCS), Pain Vigilance and Awareness Questionnaire (PVAQ), Patient Health Questionnaire (PHQ-15), Reward Probability Index (RPI), and the Activation subscale of the Behavioral Activation for Depression Scale (BADS). DISCUSSION: We expect that, after treatment, the group receiving BA should experience greater reductions in the primary and secondary outcomes than the group receiving only UC. These reductions should be both statistically and clinically significant and will be maintained at follow-up. This study will contribute to facilitate the integrated treatment of fibromyalgia and depression. TRIAL REGISTRATION: ClinicalTrials.gov under the name "Testing Interventions for Patients with Fibromyalgia and Depression," Identifier: NCT03207828 . Registered on 5 July 2017 (last update posted 21 September 2017).
引用
- Gómez-Pérez L, Vergés A, Vázquez-Taboada AR, et al. The efficacy of adding group behavioral activation to usual care in patients with fibromyalgia and major depression: design and protocol for a randomized clinical trial. Trials. 2018. PMID: 30486843. doi:10.1186/s13063-018-3037-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。